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Alemtuzumab (Campath, MabCampath) is a monoclonal
antibody targeting the CD52 antigen. Recent guidelines
recommend that this agent should be considered as ﬁrst-line
treatment in selected patients, in particular, those with 17p
deletion.
1
Importantly, alemtuzumab treatment requires special infec-
tion-related considerations, as the antibody causes severe
and prolonged lymphocytopenia.
2 Anti-infective prophylaxis
treatment and weekly monitoring for cytomegalovirus (CMV) are
recommended.
1 However, viruses other than CMV may be
reactivated following alemtuzumab therapy and cause compli-
cations.
3–6 This prompted us to analyze clinical and subclinical
virus reactivations as well as serological changes in patients who
had received alemtuzumab as ﬁrst-line monotherapy
7 and to
compare the results with patients treated with ﬂudarabine-based
combination therapy.
Eighteen chronic lymphocytic leukemia (CLL) patients
(A1-18) who participated in a phase 2 study on subcutaneous
alemtuzumab (30mg three times per week for up to 18 weeks)
as ﬁrst-line therapy
7 were compared with 27 patients (C1-27,
control group) treated with FC(R) (three received combination
therapy with rituximab, FCR). Dosing of FC(R) was as
follows: ﬂudarabine given orally 40mg/m
2 or intravenously
(IV) 25mg/m
2, days 1–3; cyclophosphamide 250mg/m
2 orally
or IV, days 1–3; rituximab 375mg/m
2 IV, day 1 (ﬁrst cycle) and
500mg/m
2, day 1 (subsequent cycles). FC(R) was given at
28-day intervals. Patient characteristics at baseline are summar-
ized in Table 1. All but two patients had CLL; one (C11) had
small lymphocytic lymphoma and one (C21) had B-cell
prolymphocytic leukemia.
Quantitative PCR was used to detect and measure the
presence of CMV, Epstein-Barr virus (EBV) and human herpes-
virus 6 (HHV-6) genomes at baseline, months 1, 2 and 3 during
therapy, end of treatment, 6 and 8–12 months after end of
therapy. Values o200 DNA copies/ml were considered nega-
tive. Qualitative PCR was used for parvovirus B19 detection.
Serology analyses were done at baseline; end of treatment and
6–12 months after end of treatment. A signiﬁcant change of
speciﬁc IgG serum content was deﬁned as follows: difference in
absorbance 40.4 for CMV, varicella zoster virus and EBV p107
(enzyme-linked immunosorbent assay); threefold change of the
U value for measles (Enzygnost, Dade Behring Marburg GmbH,
Marburg, Germany); and a fourfold change of the titer for EBV
VCA (immunoﬂuorescence).
Simultaneously, phenotyping of lymphocyte subpopulations
was performed. The frequencies of major subpopulations, that
is, CD4þ/CD3þ, CD8þ/CD3þ, CD3þ/CD56þ, CD3 /
CD56þ, CD19þ/CD5 , were estimated by ﬂow cytometry.
Response evaluation at end of therapy was performed using
the NCI-IWCLL response criteria.
8 Assessment of adverse events
was conducted according to the Common Terminology Criteria
for Adverse events v.3.0 (CTCAE, 12 December 2003).
All alemtuzumab-treated patients received anti-infective
prophylaxis consisting of valacyclovir, cotrimoxazole and
ﬂuconazole during therapy and for 8 weeks after completion
of treatment (standard type and length of prophylaxis at time of
trial).
7 One patient (A14) was not treated with cotrimoxazole
because of hypersensitivity to this agent. In the control group
10 patients received acyclovir/valacyclovir and cotrimoxazole,
one had valacyclovir only, 12 received cotrimoxazole only and
four had no prophylaxis.
Fisher exact test (two-tailed) or w
2-test (d.f.¼1) was utilized
for comparison of the incidence of virus reactivations and
changes of IgG levels. For comparison of different cell counts
non-parametric independent Mann–Whitney signed-rank test
was used.
A total of 440 PCR analyses were performed in the
alemtuzumab-treated group, among which 11 (2.5%) were
positive. All of these occurred during the time between baseline
and 2 months of therapy (Table 2). In the control group, none of
the 455 PCR analyzed samples were positive. The difference
between the two groups was statistically signiﬁcant (Po0.001).
Three of the 11 positive PCR analyses (all EBV) in the
alemtuzumab group occurred at baseline; two of these were
also positive in the subsequent analysis. Thus, the incidence
of treatment-related virus reactivations was 6/440 (1.4%) in
the alemtuzumab-treated group and 0/455 in the control group
(Po0.05).
All episodes of PCR positivity, of which all but three CMV
reactivations were asymptomatic, resolved spontaneously.
There was only one patient (A18) with a late reactivation
during unmaintained follow-up. This patient had recurrence of
symptomatic EBV reactivation (grade 3) 20 months after
completion of alemtuzumab therapy. All patients with virus
reactivation had responded to their anti-CLL treatment.
Sixteen of the alemtuzumab-treated patients and 17 of the
control patients were evaluable with regard to differences in the
IgG levels. Between baseline and 6–12 months post-therapy
there were seven (8.9%) signiﬁcant decreases and ﬁve (6.3%)
signiﬁcant increases detected among the alemtuzumab-treated
patients, the corresponding ﬁgures for the controls were
three (3.5%) and one (1.2%), respectively, (not signiﬁcant)
(Tables 3a and b).
The results of long-term analyses of immune subpopulations
in the alemtuzumab group have been published.
2 We compared
these results with the control group (data not shown). The
median number of cells within each lymphocyte subpopulation
at baseline was not statistically different. At end of treatment, the
values for all subsets were signiﬁcantly lower in the alemtuzu-
mab group. At 8–12 months after alemtuzumab therapy, the
number of cells had recovered and there was no statistically
signiﬁcant difference between the median values for the
lymphocyte subpopulations. Interestingly, the alemtuzumab-
treated patients with virus reactivation had, at end of treatment,
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Seventeen of the 18 patients (94%) in the alemtuzumab
group met the criteria for partial or complete remission.
7 The
corresponding ﬁgures for the ﬂudarabine combination-treated
group were 24 of 26 evaluable patients (92%).
This study had some limitations. The reduced number of
patients affected the statistical power, and it was a non-
randomized comparison, even though we used consecutive
control patients that were analyzed in a prospective fashion.
Table 1 Patient characteristics at baseline
Characteristic Alemtuzumab
(n¼18)
Fludarabine
combination
(n¼27)
No. of
patients
%N o . o f
patients
%
Age, years
Median 68 64
Range 56–74 57–83
Sex
Male 10 56 18 67
Female 8 44 9 33
Rai stage
00 0 0 0
I–II 5 28 14 52
III–IV 13 72 13 48
Time since initial diagnosis, months
Median 28 29
Range 1–264 1–131
WHO performance status
0–1 18 100 26 96
2–3 1 4
No. of prior anti-tumor regimens
0 18 100 17 63
19 3 3
21 4
Type of prior anti-tumor therapy
a
Chlorambucil±steroids 8
Fludarabine+cyclophosphamide 2
Alemtuzumab 1
No. of patients with IgG below
reference interval (o6.7g/l)
10 56 10 37
Abbreviations: IgG, immunoglobulin G; WHO, World Health Organization.
aMedian time from last prior treatment, months (range): 16 (4–100).
Table 2 Alemtuzumab-treated patients with positive virus PCR; virus, copy numbers (no of genome equivalents/ml) and symptoms
Patient (n¼18) Time point of PCR analyses
Baseline
(n¼18)
1 month
(n¼15)
2 months
(n¼13)
3 months
(n¼12)
End of
treatment
(n¼18)
6 months
post-therapy
(n¼17)
12 months
post-therapy
(n¼17)
A4 N N CMV
11600
NNN N
A5 N N CMV
81400
cough
NNN N
A6 EBV
2000
EBV
1800
a
N D NNN N
A7 EBV
2600
EBV
2000
ND ND N N N
A7 N HHV-6
1300
ND ND N N N
A8 N N CMV
8600
fever
NNN N
A11 N CMV
12900
N NNN N
A12 N N CMV
7900
fever
NNN N
A18 EBV
2600
N N NNN N
Total 8 (44%) Total 3 (17%) Total 4 (27%) Total 4 (31%) Total 0 Total 0 Total 0 Total 0
Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; N, negative; ND, not determined.
a2 weeks after start of therapy.
Table 3a Alemtuzumab-treated patients with one or more
signiﬁcant change of antivirus IgG level, values at 6–12 months
post-therapy compared with baseline
Patient Alemtuzumab (n¼16)
a
CMV
IgG
VZV
IgG
Measles
IgG
EBV p107
IgG
EBV
VCA IgG
A4 0 0 0 0 þ
A5 0 0 0 0 þ
A8 (¼C9)  
b    0
A12 0 0   00
A14 0 0 0 0  
A15 0 0 þ 0
A16 þ 0000
A18 0 þ
c 000
Total 1 decrease 1 decrease 2 decrease 2 decrease 1 decrease
1 increase 1 increase 1 increase 2 increase
Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus;
IgG, immunoglobulin G; VZV, varicella zoster virus; 0, no signiﬁcant
change;  , signiﬁcant decrease; +, signiﬁcant increase.
aTwo of the totally 18 patients were excluded; one because of IV
g-globulin treatment (A1) and the other because of shorter follow-up
than 6 months (A16). N¼15 for EBV p107G because of sample
shortage in one patient.
bSymptomatic reactivation, grade I, 2 months after start of treatment.
cSymptomatic reactivation, grade I, 10 months after end of treatment.
All, but patient A16, responded to alemtuzumab treatment.
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Blood Cancer JournalOur data demonstrates that, except for CMV, there was no
major increase in incidence of virus reactivation following
ﬁrst-line subcutaneous alemtuzumab compared with the FC(R)-
treated controls. The number of signiﬁcant antivirus IgG
decreases or increases did not differ signiﬁcantly between the
two treatment groups; however, the titer decreases noted in
individual patients raises the question of whether such patients
might need special infection-preventive measures to avoid
reinfection.
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Table 3b Fludarabine combination-treated patients with one or
more signiﬁcant change of antivirus IgG level, values at 6–12 months
post-therapy compared with baseline
Patient Fludarabine combination (n¼17)
a
CMV
IgG
VZV
IgG
Measles
IgG
EBV
p107 IgG
EBV
VCA IgG
C3
b 00 0 0 þ
C11 0 0 0 0  
C17 0 0 0 0  
C18   00 0 0
Total 1 decrease 0 0 0 2 decrease
1 increase
Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; IgG,
immunoglobulin G; VZV, varicella zoster virus; 0, no signiﬁcant change;
 , signiﬁcant decrease; +, signiﬁcant increase.
aNine of the totally 27 patients were not analyzed because of short
follow-up (o6 months). One patient (C13) was excluded because of
alemtzumab-treatment before the +12 month sample.
bC3¼second-line patient (FC), all the others ﬁrst-line patients.
All patients responded to ﬂudarabine combination treatment.
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